Cancer recurrence and death occurred significantly more often in ovarian cancer patients treated with erythropoietin-stimulating agents (ESAs), data from a retrospective cohort review showed.
Almost half of patients with heavily pretreated ovarian cancer benefited from an investigational PARP inhibitor, results of a phase I study showed.
Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of a small study reported here.
Most older patients with ovarian cancer may receive care that doesn't measure up to national standards, according to an analysis of a National Cancer Institute (NCI) database and Medicare claims data.
12/21/2010 Available ovarian cancer screening only slightly reduces the number of deaths from the disease, a new study finds. Until more sensitive screening tests can be developed, other strategies, such … Continued
11/08/2010 OCRF Grantee Lin Zhang, MD Research has provided strong support for the ovarian cancer stem cell hypothesis, which proposes that a rare subpopulation of tumor cells—cancer stem cells– have the … Continued
09/28/2010 View a seven-part series about ovarian cancer, brought to you by the Ovarian Cancer Research Fund.The series is narrated by Douglas A. Levine, MD, of Memorial Sloan-Kettering Cancer … Continued
Some of you may have recently seen articles in the newspaper or on TV about a test called OVA1. OVA1 is a test approved by the FDA which measures the … Continued
01/29/2010 Each year, OCRF awards millions of dollars in grants to researchers who are working to beat ovarian cancer. Our two newest grantees, Dr. Lin Zhang and Dr. Kathryn Terry, … Continued
06/08/2009 Last weekend a European study regarding the use of CA 125 testing in ovarian cancer patients was presented at the American Society of Clinical Oncologists (ASCO) Annual Meeting. The … Continued
03/17/2009 Today, the Ovarian Cancer Research Fund (OCRF) announced its most recent research grant recipients. Grants were awarded in three different categories: the Program Project Development Grant, the Liz Tilberis … Continued
On February 5, 2009, OCRF, in partnership with the Gynecologic Cancer Foundation (GCF), announced that Barbara Goff, M.D., Director of Gynecologic Oncology at the University of Washington, has been named … Continued
Get email updates about research news, action alerts, and ways to join the fight.
